Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 10Lymphoid 2CNS 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × iberdomide × CNS × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡